Acute exacerbation of interstitial lung disease
Conditions
Interventions
None listed
Sponsors
Hamamatsu University School of Medicine
Iwata City Hospital Tenryu Hospital Enshu Hospital Shizuoka General Hospital Shizuoka Saiseikai Hospital Shizuoka City Shizuoka Hospital Shizuoka City Shimizu Hospital Shizuoka Red-cross Hospital Seirei Hamamatsu Hospital Seirei Mikatahara Hospital Hamamatsu Rosai Hospital Hamamatsu Red-cross Hospital Hamamatsu Medical Center Fujieda City Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with ILD who had developed AE for the first time
Exclusion criteria
Exclusion criteria: (1) Patients undergoing chemotherapy, molecular targeted therapy, or immune checkpoint inhibitor therapy for malignancy (2) Patients with malignancy who are expected to have a prognosis of less than 1 year (3) Patients who are determined to be inappropriate for this study for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate of AE-ILD by each underlying disease - 3-month survival rate - Survival time and cumulative survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| - Relapse-free survival rate - Incidence of adverse events for each treatment - Changes in symptom scores and various laboratory findings - Risk factors for death - Risk factors for relapse or death - Risk factors for developing infections (e.g., pneumocystis pneumonia) - Treatment status - Survival rate by treatment - Development of new serum biomarkers | — |
Countries
Japan
Contacts
Public ContactHironao Hozumi
Hamamatsu University School of Medicine Second Division, Department of Internal Medicine
Outcome results
None listed